# Rural Health Rural Health[RURAL ROCKS RECALLS • ceftriaxone for injection USP SHORTAGES • Current and Resolved Drug Shortages and Discontinuations Reported to FDA FDA • Latest Drug Safety Podcast o Loperamide o OTC antacid products containing aspirin o Zecuity (sumatriptan) migraine patch • FDA Drug Safety Communication: o Numerous links • DRUG DISCONTINUATION o Zecuity (sumatriptan) Migraine o Lindane Lotion, USP 1% • FDA Approvals o Differin Gel 0.1% for over-the-counter o Dronabinol oral solution approved for chemotherapy adverse events o First Fully Dissolvable Stent • Drug Safety Labeling Changes • PATIENT SAFETY o Medscape Nephrology > Berns on Nephrology o 'Morbid and Deadly' Drug Combinations to Avoid o HHS Expands Use of Buprenophine, Eliminates Financial Incentives for Opioid Prescriptions](http://www.managedhealthcareconnect.com/content/antibiotic-recalled)

# **RECALLS**

Lupin Pharmaceuticals has launched a recall of more than 54,000 vials of ceftriaxone for injection USP in the following presentations: 250 mg, 500 mg, 1 g, and 2 g.

<http://www.managedhealthcareconnect.com/content/antibiotic-recalled>

|  |  |  |
| --- | --- | --- |
| **Presentation** | **Lot** | **Expiration** |
| 250 mg | C500031 | December 2017 |
| 250 mg | C500026 | December 2017 |
| 250 mg | C500036 | January 2018 |
| 250 mg | C500043 | January 2018 |
| 500 mg | C500006 | November 2017 |
| 500 mg | C500001 | November 2017 |
| 1 g | C400180 | July 2017 |
| 1 g | C500003 | December 2017 |
| 1 g | C500028 | December 2017 |
| 1 g | C500029 | December 2017 |
| 1 g | C500038 | January 2018 |
| 1 g | C500044 | February 2018 |
| 2 g | C500037 | January 2018 |

Drug Safety Podcast Banner Graphic

The FDA Drug Safety Podcasts are produced by FDA's Center for Drug Evaluation and Research (CDER). They provide emerging safety information about drugs in conjunction with the release of Public Health Advisories and other drug safety issues. **Latest** **Drug Safety Podcasts**

| **Title** | **Date** | **Link to Podcast** | **Link to Transcript** |
| --- | --- | --- | --- |
| FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse | June 7, 2016 | [Listen to This Podcast](http://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyPodcasts/UCM506834.mp3) *Run Time:  00:3:00* | [Transcript](http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm506835.htm) |
| FDA warns about serious bleeding risk with over-the-counter antacid products containing aspirin | June 6, 2016 | [Listen to This Podcast](http://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyPodcasts/UCM505553.mp3) *Run Time:  00:3:00* | [Transcript](http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm505554.htm) |
| FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patch | June 2, 2016 | [Listen to This Podcast](http://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyPodcasts/UCM505619.mp3) *Run Time:  00:1:58* | [Transcript](http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm505621.htm) |

**FDA Drug Safety Communication:**

* [FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)   
  6/14/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse   
  6/7/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA warns about serious bleeding risk with over-the-counter antacid products containing aspirin   
  6/6/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patch   
  6/2/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death   
  5/19/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate   
  5/18/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together   
  5/12/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA warns about rare but serious skin reactions with mental health drug olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax)   
  5/10/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)   
  5/3/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA approves brand name change for antidepressant drug Brintellix (vortioxetine) to avoid confusion with antiplatelet drug Brilinta (ticagrelor)   
  5/2/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA to review study examining use of oral fluconazole (Diflucan) in pregnancy   
  4/26/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function   
  4/8/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin   
  4/5/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes   
  3/22/2016](http://www.fda.gov/default.htm)
* [FDA Drug Safety Communication: FDA cautions about dosing errors when switching between different oral formulations of antifungal Noxafil (posaconazole); label changes approved   
  1/4/2016](http://www.fda.gov/default.htm)

**SHORTAGES**

**Current and Resolved Drug Shortages and Discontinuations Reported to FDA**

o   <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>

**July 05, 2016**  ([http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm#tabs-4](http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm" \l "tabs-4))

* [Piperacillin and Tazobactam (Zosyn) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Piperacillin+and+Tazobactam+%28Zosyn%29+Injection&st=c&tab=tabs-4&panels=0) (***Currently in Shortage***)

**June 02, 2016**

* [Lindane Lotion, USP 1%](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lindane+Lotion%2C+USP+1per&st=d&tab=tabs-4&panels=0) (***Discontinuation***)

**May 24, 2016**

* [Terbinafine (Lamisil) Oral Granules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Terbinafine+%28Lamisil%29+Oral+Granules&st=d&tab=tabs-4&panels=0) (***Discontinuation***)

**May 10, 2016**

* [Cyclosporine Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cyclosporine+Capsules&st=d&tab=tabs-4&panels=0) (***Discontinuation***)
* [Imipenem and Cilastatin for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Imipenem+and+Cilastatin+for+Injection%2C+USP&st=d&tab=tabs-4&panels=0) (***Discontinuation***)

**April 26, 2016**

* [Fluphenazine Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Fluphenazine+Tablets&st=d&tab=tabs-4&panels=0) (***Discontinuation***)

| **Generic Name or Active Ingredient** | **Status** |
| --- | --- |
| [Acetohydroxamic Acid (Lithostat) Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Acetohydroxamic%20Acid%20%28Lithostat%29%20Tablets&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Ammonium Chloride Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Ammonium%20Chloride%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Anagrelide Hydrochloride Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Anagrelide%20Hydrochloride%20Capsules&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Aprepitant (Emend) Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Aprepitant%20%28Emend%29%20Capsules&st=r&tab=tabs-1) | ***Resolved*** |
| [Atropine Sulfate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine%20Sulfate%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Azathioprine Tablet](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Azathioprine%20Tablet&st=r&tab=tabs-1) | ***Resolved*** |
| [Bleomycin Sulfate for Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bleomycin%20Sulfate%20for%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Caffeine Anhydrous (125mg/mL); Sodium Benzoate (125mg/mL) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Caffeine%20Anhydrous%20%28125mg/mL%29;%20Sodium%20Benzoate%20%28125mg/mL%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Calcium Chloride Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Calcium%20Chloride%20Injection,%20USP&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Calcium Gluconate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Calcium%20Gluconate%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Cefazolin Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cefazolin%20Injection&st=r&tab=tabs-1) | ***Resolved*** |
| [Cefepime Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cefepime%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Cefotaxime Sodium (Claforan) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cefotaxime%20Sodium%20%28Claforan%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Cefotetan Disodium Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cefotetan%20Disodium%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Chloramphenicol Sodium Succinate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Chloramphenicol%20Sodium%20Succinate%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Chloroquine Phosphate Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Chloroquine%20Phosphate%20Tablets&st=r&tab=tabs-1) | ***Resolved*** |
| [Desmopressin Acetate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Desmopressin%20Acetate%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Dexamethasone Sodium Phosphate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dexamethasone%20Sodium%20Phosphate%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Dextrose 5% Injection Bags](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dextrose%205per%20Injection%20Bags&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Dextrose Injection USP, 70%](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dextrose%20Injection%20USP,%2070per&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Disopyramide Phosphate (Norpace) Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Disopyramide%20Phosphate%20%28Norpace%29%20Capsules&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Doxorubicin (Adriamycin) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Doxorubicin%20%28Adriamycin%29%20Injection&st=r&tab=tabs-1) | ***Resolved*** |
| [Doxorubicin Lyophilized Powder for Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Doxorubicin%20Lyophilized%20Powder%20for%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Epinephrine Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Epinephrine%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Eptifibatide (Integrilin) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Eptifibatide%20%28Integrilin%29%20Injection&st=r&tab=tabs-1) | ***Resolved*** |
| [Ethiodized Oil (Lipiodol) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Ethiodized%20Oil%20%28Lipiodol%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Fentanyl Citrate (Sublimaze) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Fentanyl%20Citrate%20%28Sublimaze%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Fomepizole Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Fomepizole%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Gemifloxacin Mesylate (Factive) Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Gemifloxacin%20Mesylate%20%28Factive%29%20Tablets&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Haloperidol Lactate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Haloperidol%20Lactate%20Injection&st=r&tab=tabs-1) | ***Resolved*** |
| [Imipenem and Cilastatin for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Imipenem%20and%20Cilastatin%20for%20Injection,%20USP&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Indigotindisulfonate Sodium (Indigo Carmine) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Indigotindisulfonate%20Sodium%20%28Indigo%20Carmine%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Ketorolac Tromethamine Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Ketorolac%20Tromethamine%20Injection&st=r&tab=tabs-1) | ***Resolved*** |
| [L-Cysteine Hydrochloride Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=L-Cysteine%20Hydrochloride%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Leucovorin Calcium Lyophilized Powder for Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Leucovorin%20Calcium%20Lyophilized%20Powder%20for%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Leuprolide Acetate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Leuprolide%20Acetate%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Levetiracetam (Keppra) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Levetiracetam%20%28Keppra%29%20Injection&st=r&tab=tabs-1) | ***Resolved*** |
| [Lidocaine Hydrochloride (Xylocaine) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20%28Xylocaine%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [LifeCare PCA™ Sterile Empty Vial and Injector](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=LifeCare%20PCA%E2%84%A2%20Sterile%20Empty%20Vial%20and%20Injector&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Liotrix (Thyrolar) Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liotrix%20%28Thyrolar%29%20Tablets&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Mecasermin [rDNA origin] (Increlex) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Mecasermin%20%5brDNA%20origin%5d%20%28Increlex%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Memantine Hydrochloride (Namenda) XR Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Memantine%20Hydrochloride%20%28Namenda%29%20XR%20Capsules&st=r&tab=tabs-1) | ***Resolved*** |
| [Meropenem for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Meropenem%20for%20Injection,%20USP&st=r&tab=tabs-1) | ***Resolved*** |
| [Methyldopate Hydrochloride Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methyldopate%20Hydrochloride%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Methylphenidate Hydrochloride ER Capsules/Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20ER%20Capsules/Tablets&st=r&tab=tabs-1) | ***Resolved*** |
| [Methylprednisolone Sodium Succinate for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylprednisolone%20Sodium%20Succinate%20for%20Injection,%20USP&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Metoprolol Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Metoprolol%20Injection&st=r&tab=tabs-1) | ***Resolved*** |
| [Morphine Sulfate Injection, USP, CII, (Preservative-Free)(For PCA Use Only)](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Morphine%20Sulfate%20Injection,%20USP,%20CII,%20%28Preservative-Free%29%28For%20PCA%20Use%20Only%29&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Multi-Vitamin Infusion (Adult and Pediatric)](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Multi-Vitamin%20Infusion%20%28Adult%20and%20Pediatric%29&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Mupirocin Calcium Nasal Ointment](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Mupirocin%20Calcium%20Nasal%20Ointment&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Nebivolol (BYSTOLIC) Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Nebivolol%20%28BYSTOLIC%29%20Tablets&st=r&tab=tabs-1) | ***Resolved*** |
| [Nimodipine (Nymalize) Oral Solution](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Nimodipine%20%28Nymalize%29%20Oral%20Solution&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Penicillin G Benzathine (Bicillin L-A) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Penicillin%20G%20Benzathine%20%28Bicillin%20L-A%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Peritoneal Dialysis Solutions](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Peritoneal%20Dialysis%20Solutions&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Phentolamine Mesylate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Phentolamine%20Mesylate%20Injection&st=r&tab=tabs-1) | ***Resolved*** |
| [Piperacillin and Tazobactam (Zosyn) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Piperacillin%20and%20Tazobactam%20%28Zosyn%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Potassium Acetate Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Potassium%20Acetate%20Injection,%20USP&st=r&tab=tabs-1) | ***Resolved*** |
| [Potassium Chloride Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Potassium%20Chloride%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Reserpine Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Reserpine%20Tablets&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Sacrosidase (Sucraid) Oral Solution](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sacrosidase%20%28Sucraid%29%20Oral%20Solution&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Sodium Acetate Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Acetate%20Injection,%20USP&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Sodium Bicarbonate Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection,%20USP&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Sodium Chloride 0.9% Injection Bags](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Chloride%200.9per%20Injection%20Bags&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Sodium Chloride 23.4% Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Chloride%2023.4per%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Sufentanil Citrate (Sufenta) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sufentanil%20Citrate%20%28Sufenta%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Sumatriptan (Imitrex) Nasal Spray](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sumatriptan%20%28Imitrex%29%20Nasal%20Spray&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Technetium Tc99m Succimer Injection (DMSA)](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Technetium%20Tc99m%20Succimer%20Injection%20%28DMSA%29&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Theophylline Extended Release Tablets and Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Theophylline%20Extended%20Release%20Tablets%20and%20Capsules&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Tigecycline (Tygacil) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tigecycline%20%28Tygacil%29%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Tiopronin (Thiola)](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tiopronin%20%28Thiola%29&st=r&tab=tabs-1) | ***Resolved*** |
| [Tobramycin Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tobramycin%20Injection&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Tretinoin Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tretinoin%20Capsules&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Triamcinolone Hexacetonide Injectable Suspension (Aristospan)](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Triamcinolone%20Hexacetonide%20Injectable%20Suspension%20%28Aristospan%29&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Trimipramine Maleate (SURMONTIL) Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Trimipramine%20Maleate%20%28SURMONTIL%29%20Capsules&st=c&tab=tabs-1) | ***Currently in Shortage*** |
| [Vancomycin Hydrochloride for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Vancomycin%20Hydrochloride%20for%20Injection,%20USP&st=c&tab=tabs-1) | ***Currently in Shortage*** |

**DRUG DISCONTINUATION**

**Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars**

o   [**http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm504736.htm?source=govdelivery&utm\_medium=email&utm\_source=govdelivery**](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm504736.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)

Lindane Lotion, USP 1%

|  |  |  |
| --- | --- | --- |
| 10mg/g, 60mL / 2oz. Plastic Bottle (NDC 60432-833-60) | 06/02/2016 | Wockhardt/MGP has made the decision to discontinue the manufacture of this product. |

o   <http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lindane+Lotion%2C+USP+1per&source=govdelivery&st=d&tab=tabs-4&utm_medium=email&utm_source=govdelivery>

**FDA**

**FDA approves Differin Gel 0.1% for over-the-counter use to treat acne**

o   <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm510362.htm>

[FDA approval alert: Dronabinol oral solution approved for chemotherapy adverse events](http://journalofclinicalpathways.com/news/fda-approval-alert-dronabinol-oral-solution-approved-chemotherapy-adverse-events)

o   <http://journalofclinicalpathways.com/resource/supportive_care>

# **FDA Approves First Fully Dissolvable Stent**

ois absorbed by the body after about three years

o   <https://www.nlm.nih.gov/medlineplus/news/fullstory_159721.html>

**Drug Safety Labeling** Changes

o   <http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509048.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery>

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | |  | **SECTIONS MODIFIED** | | | | | | | (Click on drug name to go to detailed view) | **BW** | **C** | **W** | **P** | **AR** | **PPI/MG** | | [Elitek (rasburicase)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm450148.htm) | X |  | X | X | X | PCI | | [Sabril (vigabatrin) Tablet  Sabril (vigabatrin) Oral Solution](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm335401.htm) | X |  | X | X | X | PCI, MG | | [Xigduo XR (dapagliflozin and metformin HCl extended-release)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509073.htm) | X | X | X | X | X | PCI, MG | | (Click on drug name to go to detailed view) | **BW** | **C** | **W** | **P** | **AR** | **PPI/MG** | | [Aubagio (teriflunomide)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm423101.htm) |  | X | X | X | X | PCI, MG | | [Farxiga (dapagliflozin)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm413415.htm) |  | X | X | X | X | PCI, MG | | [Hectorol (doxercalciferol)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509072.htm) |  | X | X |  | X |  | | [Nitromist (nitroglycerin)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509070.htm) |  | X |  | X |  |  | | [Technivie (ombitasvir, paritaprevir and ritonavir) Tablets](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm471849.htm) |  | X |  | X |  | PCI, MG | | [Tybost (cobicistat)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm476799.htm) |  | X | X | X |  | PCI, PI | |  |  |  |  |  |  |  | |  |  |  |  |  |  |  | | (Click on drug name to go to detailed view) | **BW** | **C** | **W** | **P** | **AR** | **PPI/MG** | | [Afinitor (everolimus)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258494.htm) |  |  | X | X | X |  | | [Bendeka (bendamustine hydrochloride)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509558.htm) |  |  | X | X | X |  | | [Children's Motrin (ibuprofen)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509079.htm) |  |  | X |  |  |  | | [Farydak (panobinostat)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509069.htm) |  |  | X | X |  | PCI, MG | | [Humira (adalimumab)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm194134.htm) |  |  | X | X | X | MG | | [Iclusig (ponatinib hydrochloride)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm380782.htm) |  |  | X | X | X | MG | | [Lybrel (levonorgestrel and ethinyl estradiol)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509076.htm) |  |  | X |  |  |  | | [Natpara (parathyroid hormone)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509075.htm) |  |  | X | X |  |  | | [Orfadin (nitisinone)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm342976.htm) |  |  | X | X | X | PCI | | [Prezista (darunavir) Tablet and Oral Suspension](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm287579.htm) |  |  | X | X | X | PCI, PI | | [Stivarga (regorafenib)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm355781.htm) |  |  | X | X |  | PCI | | [Tamiflu (oseltamivir phosphate) Capsules and Oral Suspension](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm234013.htm) |  |  | X | X | X | PCI, PI | | [Tyvaso (treprostinil)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm352041.htm) |  |  | X | X | X |  | |  |  |  |  |  |  |  | | (Click on drug name to go to detailed view) | BW | C | W | P | AR | PPI/MG | | [Zosyn (piperacillin and tazobactam for injection) and Zosyn (piperacillin sodium and tazobactam sodium injection)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm371312.htm) |  |  | X | X | X | PCI | | [Avycaz (ceftazidime and avibactam)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509559.htm) |  |  |  | X | X |  | | [Cardura (doxazosin)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm200287.htm) |  |  |  | X |  |  | | [Cerebyx (fosphenytoin sodium)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm283239.htm) |  |  |  | X |  |  | | [Dilantin (phenytoin) Injection, Dilantin (phenytoin) Oral Suspension](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm384789.htm) |  |  |  | X | X |  | | [Envarsus XR (tacrolimus extended release)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm509560.htm) |  |  |  | X |  |  | | [Kuvan (sapropterin dihydrochloride)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm396538.htm) |  |  |  | X | X | PCI | | [Pomalyst (pomalidomide)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm446484.htm) |  |  |  | X | X | PCI, MG | | [Tivicay (dolutegravir)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm400438.htm) |  |  |  | X |  | PCI, PI | | [Viekira PAK (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm458365.htm) |  |  |  | X |  |  | | (Click on drug name to go to detailed view) | **BW** | **C** | **W** | **P** | **AR** | **PPI/MG** | | [DEPO-PROVERA (medroxyprogesterone acetate)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm232329.htm) |  |  |  |  | X |  | | [Elelyso (taliglucerase alfa)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm413395.htm) |  |  |  |  | X |  | | [Imbruvica (ibrutinib)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm433426.htm) |  |  |  |  | X |  | | [Opsumit (macitentan)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm446379.htm) |  |  |  |  | X |  | | [Seroquel (quetiapine fumarate) and Seroquel XR (quetiapine fumarate)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm352032.htm) |  |  |  |  | X |  | | [Xyzal (levocetirizine dihydrochloride Oral Tabs) Xyzal (levocetirizine dihydrochloride Oral Solution)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm250634.htm) |  |  |  |  | X |  | | [Zaltrap (ziv-aflibercept) Injection](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm374591.htm) |  |  |  |  | X |  | | [Zyban (Bupropion Hydrochloride)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm229405.htm) |  |  |  |  | X |  | |  |  |  |  |  |  |  | |  |  |  |  |  |  |  | |  |  |  |  |  |  |  | |  |  |  |  |  |  |  | | (Click on drug name to go to detailed view) | **BW** | **C** | **W** | **P** | **AR** | **PPI/MG** | | [LUPRON DEPOT (leuprolide acetate for depot suspension)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262554.htm) |  |  |  |  |  | PCI | | [Neupogen (filgrastim)](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm219032.htm) |  |  |  |  |  | PCI |  |  | | --- | | **PATIENT SAFETY** | |  |
|  |  |  |

[Medscape Nephrology](http://www.medscape.com/nephrology) > [Berns on Nephrology](http://www.medscape.com/index/list_3468_0)

**'Morbid and Deadly' Drug Combinations to Avoid**

o   <http://www.medscape.com/viewarticle/844846>

**OPIOIDS**

o**HHS Expands Use of Buprenophine, Eliminates Financial Incentives for Opioid Prescriptions**

o[http://www.managedhealthcareconnect.com/content/hhs-expands-use-buprenophine-eliminates-financial-incentives-opioid-prescriptions](http://www.managedhealthcareconnect.com/content/hhs-expands-use-buprenophine-eliminates-financial-incentives-opioid-prescriptions" \o "managed healthcare connect)

**IMMUNIZATIONS**

CDC Vaccine Price List

o   <http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html>

o   [CDC](http://www.cdc.gov/)[News and Media Resources Home](http://www.cdc.gov/vaccines/news/index.html)[Immunization-related News](http://www.cdc.gov/vaccines/news/related.html)

Immunization MMWRs

o   <http://www.cdc.gov/vaccines/news/news-pubs/>

**Study: HPV Vaccine Beneficial for Women Older than 25**

o   <http://www.managedhealthcareconnect.com/content/adult-women-also-benefit-hpv-vaccination>

**INSURANCE**

**Proposed Policy, Payment, and Quality Provisions Changes to the Medicare Physician Fee Schedule for Calendar Year (CY) 2017**

o   [**https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-07-07-2.html**](https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-07-07-2.html)

**NEWS**

**Cut the Meat to Curb Diabetes**

o   <http://www.consultant360.com/exclusives/cut-meat-curb-diabetes>

The FDA has withdrawn approvals for the administration of [niacin](http://www.consultant360.com/search?search_api_views_fulltext=niacin&op=GO) and fenofibric acid

o**[http://www.consultant360.com/exclusives/fda-pulls-approval-niacin-fibrate-combination-statins](http://www.consultant360.com/exclusives/fda-pulls-approval-niacin-fibrate-combination-statins" \o "Consultant 360) Warning Leads to Increased Hospitalization, Death**

**Multistate Outbreak of *Burkholderia cepacia* Infections**

o   <http://www.cdc.gov/hai/outbreaks/b-cepacia/index.html?source=govdelivery&utm_medium=email&utm_source=govdelivery>

# **Naloxone Coprescribing Beneficial for Primary Care Patients on Long-Term Opioids**

o   <http://www.empr.com/news/naloxone-coprescribing-beneficial-for-primary-care-patients-on-long-term-opioids/article/506123/>

[**Vitamin D and physical function: Is more better?**](http://www.health.harvard.edu/blog/vitamin-d-and-physical-function-is-more-better-201602269206)

o   <http://www.health.harvard.edu/blog/vitamin-d-and-physical-function-is-more-better-201602269206?utm_source=delivra&utm_medium=email&utm_campaign=BF20160704-Caregivers&utm_id=189352&mid=11154540&ml=189352>

**Provider status**

o[http://drugtopics.modernmedicine.com/drug-topics/news/provider-status?page=0,4&cfcache=true](http://drugtopics.modernmedicine.com/drug-topics/news/provider-status?page=0,4&cfcache=true" \o "Drug Topics)

**4 in 10 Popular Sunscreens Don't Meet Sun Safety Standards: Study**

o   <https://www.nlm.nih.gov/medlineplus/news/fullstory_159734.html>

**Seniors With Access to Medical Marijuana Use Fewer Prescription Drugs**

o**[http://www.managedhealthcareconnect.com/content/seniors-access-medical-marijuana-use-fewer-prescription-drugs](http://www.managedhealthcareconnect.com/content/seniors-access-medical-marijuana-use-fewer-prescription-drugs" \o "Managed Healthcare Connect)**

**Bupropion use may be linked with lower glaucoma risk**

o**[http://www.managedhealthcareconnect.com/content/bupropion-use-may-be-linked-lower-glaucoma-risk](http://www.managedhealthcareconnect.com/content/bupropion-use-may-be-linked-lower-glaucoma-risk" \o "Managed Healthcare Connect)**

**FDA to Restrict Compounders from Making Copies of Commercially Available Drugs**

o[Posted 07 July 2016](http://raps.org/Regulatory-Focus/News/2016/07/07/25289/FDA-to-Restrict-Compounders-from-Making-Copies-of-Commercially-Available-Drugs/?utm_source=Email&utm_medium=Informz&utm_campaign=RF%2DToday) By [Zachary Brennan](http://raps.org/SearchRegFocus.aspx?name=Zachary%20Brennan)

oSee more at: <http://raps.org/Regulatory-Focus/News/2016/07/07/25289/FDA-to-Restrict-Compounders-from-Making-Copies-of-Commercially-Available-Drugs/?utm_source=Email&utm_medium=Informz&utm_campaign=RF%2DToday#sthash.zZk2ZVRv.dpuf>

[**http://raps.org/Regulatory-Focus/News/2016/07/07/25289/FDA-to-Restrict-Compounders-from-Making-Copies-of-Commercially-Available-Drugs/?utm\_source=Email&utm\_medium=Informz&utm\_campaign=RF%2DToday**](http://raps.org/Regulatory-Focus/News/2016/07/07/25289/FDA-to-Restrict-Compounders-from-Making-Copies-of-Commercially-Available-Drugs/?utm_source=Email&utm_medium=Informz&utm_campaign=RF%2DToday)

**Many popular sunscreens don't meet suggested guidelines**

o[http://www.managedhealthcareconnect.com/content/many-popular-sunscreens-dont-meet-suggested-guidelines](http://www.managedhealthcareconnect.com/content/many-popular-sunscreens-dont-meet-suggested-guidelines" \o "Managed Health Care Connect)

**This content is copyright protected**

However, if you would like to share the information in this article, you may use the headline, summary and link below:

[US FDA slams two Chinese API makers for quality systems and data issues](http://www.in-pharmatechnologist.com/Ingredients/US-FDA-slams-two-China-API-makers-for-quality-systems-and-data-issues?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

By [Dan Stanton+](https://plus.google.com/115431563038684828224?rel=author), 29-Jun-2016

Quality system and data integrity issues have landed two Chinese API makers with US FDA warning letters.

o   [http://www.in-pharmatechnologist.com/Ingredients/US-FDA-slams-two-China-API-makers-for-quality-systems-and-data-issues](http://www.in-pharmatechnologist.com/Ingredients/US-FDA-slams-two-China-API-makers-for-quality-systems-and-data-issues?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

**This content is copyright protected**

However, if you would like to share the information in this article, you may use the headline, summary and link below:

[Two component ‘bio-ink’ could help advance 3D printing of tissues](http://www.biopharma-reporter.com/Bio-Developments/Two-component-bio-ink-could-help-advance-3D-printing-of-tissues?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

By Phil Taylor, 06-Jul-2016

Researchers in the UK say they have developed a ‘bio-ink’, which overcomes obstacles holding back the use of 3D printing to make complex tissues.

**This content is copyright protected**

However, if you would like to share the information in this article, you may use the headline, summary and link below:

[J&J's insulin patch finally heading for launch](http://www.in-pharmatechnologist.com/Drug-Delivery/J-J-s-insulin-patch-finally-heading-for-launch?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

By [Gareth MacDonald+](https://plus.google.com/101368984263298352439?rel=author), 05-Jul-2016

Johnson & Johnson has finally announced a launch schedule for its One Touch Via insulin patch - some four years after it was first approved in the US.

[http://www.in-pharmatechnologist.com/Drug-Delivery/J-J-s-insulin-patch-finally-heading-for-launch](http://www.in-pharmatechnologist.com/Drug-Delivery/J-J-s-insulin-patch-finally-heading-for-launch?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

**This content is copyright protected**

However, if you would like to share the information in this article, you may use the headline, summary and link below:

[US FDA slams two Chinese API makers for quality systems and data issues](http://www.in-pharmatechnologist.com/Ingredients/US-FDA-slams-two-China-API-makers-for-quality-systems-and-data-issues?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

By [Dan Stanton+](https://plus.google.com/115431563038684828224?rel=author), 29-Jun-2016

Quality system and data integrity issues have landed two Chinese API makers with US FDA warning letters.

[http://www.in-pharmatechnologist.com/Ingredients/US-FDA-slams-two-China-API-makers-for-quality-systems-and-data-issues](http://www.in-pharmatechnologist.com/Ingredients/US-FDA-slams-two-China-API-makers-for-quality-systems-and-data-issues?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

**This content is copyright protected**

However, if you would like to share the information in this article, you may use the headline, summary and link below:

[Two component ‘bio-ink’ could help advance 3D printing of tissues](http://www.biopharma-reporter.com/Bio-Developments/Two-component-bio-ink-could-help-advance-3D-printing-of-tissues?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

By Phil Taylor, 06-Jul-2016

Researchers in the UK say they have developed a ‘bio-ink’, which overcomes obstacles holding back the use of 3D printing to make complex tissues.

o   [http://www.biopharma-reporter.com/Bio-Developments/Two-component-bio-ink-could-help-advance-3D-printing-of-tissues](http://www.biopharma-reporter.com/Bio-Developments/Two-component-bio-ink-could-help-advance-3D-printing-of-tissues?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)